Cancer, cardiovascular, neurodegenerative, infectious and autoimmune diseases are among the leading causes of disease burden for patients and society. The Center for Translational Molecular Medicine (CTMM) was established in 2008 to address these areas, supported by FES funding (Dutch natural gas reserve fund).
CTMM helps to drive the development of molecular diagnostics and molecular imaging technologies, focusing on translational aspects of molecular medicine. The goal is to ensure that scientific results can be applied as quickly as possible in patient care – with earlier and more precise diagnosis of disease, and the design of highly personalized therapies.
All Dutch university medical centers, several universities, and more than 90 companies have been involved in a wide range of CTMM research projects. These projects combine R&D, clinical resources, and research infrastructure so that patients with complex diseases can benefit from innovative treatments. A strong translational focus is reflected by financial support for the projects that comes from six Dutch health foundations. In all, CTMM has 133 partners, with €321 million in allocated budget until the end of 2015, and is part of 32 projects/consortia.